Key result
Pediatric Ebstein's anomaly surgery cuts moderate-to-severe tricuspid regurgitation by ~66% at mid-term follow-up.
Why the study?
Surgery is the main treatment for Ebstein anomaly, but surgical results required summarization.
Does surgical treatment improve mid-term outcomes in pediatric patients with Ebstein's Anomaly?
Cohort (n=80)
No
Does surgical treatment improve mid-term outcomes in pediatric patients with Ebstein's Anomaly?
Absolute Event Rate: 31.9% vs 92.5%
p-value: p=<0.001
This study reports on the mid-term outcomes of surgical treatment for pediatric patients with Ebstein's Anomaly.
Surgery was associated with reduced TR in pediatric Ebstein's; leaves open randomized trials on optimal timing and survival.
Background: Ebstein's anomaly (EA) is a malformation of the tricuspid valve (TV) and myopathy of the right ventricle (RV). Surgery is now the main treatment for the defect. Objective: To summarize our surgical results and ... | Find, read and cite all the research you need on Tech Science Press
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) conducted a cohort in Ebstein's Anomaly (n=80). Surgical treatment (biventricular, 1.5-ventricle, or univentricular repair) vs. Preoperative condition was evaluated on Moderate-severe tricuspid regurgitation (p=<0.001). Surgical treatment for pediatric Ebstein's anomaly significantly decreased moderate-to-severe tricuspid regurgitation from 92.5% preoperatively to 31.9% at mid-term follow-up.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: